Clinical Trials and Research

ExtractTransthyretin amyloid cardiomyopathy (ATTR-CM) is an increasingly recognized cause of heart failure with a complex and heterogeneous disease course. Accurate…

AbstractBackground: Transthyretin amyloidosis cardiomyopathy (ATTR-CM) is an infiltrative cardiomyopathy and an increasingly recognized cause of heart failure. With…

Amvuttra (vutrisiran) rapidly and consistently reduces blood levels of transthyretin (TTR), the disease-causing protein in hereditary transthyretin amyloidosis with…

AbstractBackgroundTransthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive infiltrative disease of the myocardium. Early diagnosis is essential for the…

AbstractBackground: In low-flow, low-gradient aortic stenosis (LFLG AS), restricted aortic valve opening may represent either fixed valvular obstruction or flow-…

The Cardiac Amyloidosis Pipeline Analysis Report by Expert Market Research gives comprehensive insights into cardiac amyloidosis therapeutics currently undergoing…

AbstractThis viewpoint highlights the critical need for a standardized definition of heart failure (HF) endpoints in clinical trials specific to transthyretin…

AbstractCardiac immunoglobulin light chain (AL) amyloidosis classically presents with biventricular heart failure and increased wall thickness. Recurrent unilateral…

AbstractBackground: Transthyretin amyloidosis with cardiomyopathy (ATTR-CM) is underdiagnosed in heart failure with preserved ejection fraction. Although disease-…

AbstractBackgroundTransthyretin amyloid cardiomyopathy (ATTR-CM) coexists in up to 15% of elderly patients with severe aortic stenosis (AS), presenting complex…